These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12783617)

  • 1. Immunotherapy for autoimmune and inflammatory renal diseases.
    Booth AD; Firth JD; Jayne DR
    Expert Opin Biol Ther; 2003 Jun; 3(3):487-500. PubMed ID: 12783617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells in immune-mediated renal disease.
    Ghali JR; Wang YM; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2016 Feb; 21(2):86-96. PubMed ID: 26206106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for autoimmune and inflammatory renal diseases.
    Jayne DR
    Curr Opin Nephrol Hypertens; 1998 May; 7(3):311-5. PubMed ID: 9617563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mycophenolate mofetil in autoimmune and renal diseases.
    Appel GB; Radhakrishnan J; Ginzler EM
    Transplantation; 2005 Oct; 80(2 Suppl):S265-71. PubMed ID: 16251859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas.
    Casey TP
    N Z Med J; 1973 Oct; 79(500):290-5. PubMed ID: 4519116
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.
    Kronbichler A; Kerschbaum J; Mayer G
    J Immunol Res; 2015; 2015():858027. PubMed ID: 26078982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.
    Ghali JR; Holdsworth SR; Kitching AR
    Curr Med Chem; 2015; 22(38):4341-65. PubMed ID: 26521930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
    Cagnoli L;
    G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogenesis and anticoagulant treatment of autoimmune diseases of the kidneys (review of the literature)].
    Shul'tsev GP; Gilunova NI; Tsalenchuk IaP
    Ter Arkh; 1971 Nov; 43(11):18-23. PubMed ID: 4948318
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma cells as an innovative target in autoimmune disease with renal manifestations.
    Hiepe F; Radbruch A
    Nat Rev Nephrol; 2016 Apr; 12(4):232-40. PubMed ID: 26923204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for the treatment of autoimmune renal diseases.
    Holdsworth SR; Gan PY; Kitching AR
    Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lupus nephritis].
    Morović-Vergles J; Salamon L
    Reumatizam; 2009; 56(2):34-40. PubMed ID: 20429260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.
    Ostrov BE
    Immunol Invest; 2015; 44(8):777-802. PubMed ID: 26575464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic trials in lupus nephritis. Problems related to renal histology, monitoring of therapy and measures of outcome.
    Balow JE
    Nephron; 1981; 27(4-5):171-6. PubMed ID: 7022237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
    Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
    J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative study of the activity of a natural peptide complex in the kidneys and its synthetic analogs in autoimmune nephritis].
    Geĭko OA; Bobrova NA; Kaĭdashev IP
    Eksp Klin Farmakol; 1998; 61(4):44-7. PubMed ID: 9783109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of corticosteroids in renal disease.
    Lawrence JR
    Drugs; 1974; 8(6):438-47. PubMed ID: 4156322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.